Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Gains from Sales and Divestitures (2019 - 2022)

P3 Health Partners (PIII) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $5.0 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Gains from Sales and Divestitures changed N/A year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Dec 2022, changed N/A, and an annual FY2022 reading of $5.0 million, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $5.0 million for Q4 2022 at P3 Health Partners, up from $5.0 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $5.0 million in Q4 2022 and bottomed at $443750.0 in Q4 2020.
  • Average Gains from Sales and Divestitures over 4 years is $2.5 million, with a median of $660417.0 recorded in 2021.
  • Peak annual rise in Gains from Sales and Divestitures hit 29.93% in 2020, while the deepest fall reached 29.93% in 2020.
  • Year by year, Gains from Sales and Divestitures stood at $633333.0 in 2019, then fell by 29.93% to $443750.0 in 2020, then skyrocketed by 48.83% to $660417.0 in 2021, then surged by 662.85% to $5.0 million in 2022.
  • Business Quant data shows Gains from Sales and Divestitures for PIII at $5.0 million in Q4 2022, $5.0 million in Q3 2022, and $4.9 million in Q2 2022.